Fig. 3
From: NLRP3 inflammasome as a potential treatment in ischemic stroke concomitant with diabetes
Novel treatment strategies to reduce infarct size by inhibiting the NLRP3 inflammasome in a mouse model of middle cerebral artery occlusion. The cerebral infarction of mice with stroke or diabetic-stroke, and treated or genetically modified, is shown. Diabetic mice had significantly larger infarcts. The activation of NLRP3 inflammation is a crucial step after stroke and diabetes. Targeting NLRP3 inflammasome formation or its products (IL-1β) by using NLRP3-specific siRNA to genetically delete any inflammatory component (NLRP3, ASC or caspase 1), or a selective NLRP3 inhibitor, is an important new avenue in stroke treatment